|
Originally published In Press as doi:10.1074/jbc.M204581200 on August 9, 2002
J. Biol. Chem., Vol. 277, Issue 42, 40106-40111, October 18, 2002
Accumulation of 99Mo-containing Iron-Molybdenum
Cofactor Precursors of Nitrogenase on NifNE, NifH, and NifX of
Azotobacter vinelandii*
Priya
Rangaraj § and
Paul W.
Ludden ¶
From the ¶ Department of Biochemistry and the
Center for the Study of Nitrogen Fixation, College of
Agricultural and Life Sciences, University of Wisconsin-Madison,
Madison, Wisconsin 53706
Received for publication, May 9, 2002, and in revised form, August 1, 2002
 |
ABSTRACT |
The biosynthesis of the iron-molybdenum cofactor
(FeMo-co) of nitrogenase was investigated using the purified in
vitro FeMo-co synthesis system and 99Mo. The purified
system involves the addition of all components that are known to be
required for FeMo-co synthesis in their purified forms. Here, we report
the accumulation of a 99Mo-containing FeMo-co precursor on
NifNE. Apart from NifNE, NifH and NifX also accumulate 99Mo
label. We present evidence that suggests NifH may serve as the entry
point for molybdenum incorporation into the FeMo-co biosynthetic
pathway. We also present evidence suggesting a role for NifX in
specifying the organic acid moiety of FeMo-co.
 |
INTRODUCTION |
Dinitrogenase (NifKD, MoFe-protein) and dinitrogenase reductase
(NifH, Fe-protein) comprise the two-component complex metalloenzyme nitrogenase (1). Dinitrogenase is an 2 2
heterotetramer of the nifK and D gene products,
while dinitrogenase reductase is an 2 homodimer of the
nifH gene product. The iron-molybdenum cofactor
(FeMo-co)1 is the site of
substrate reduction (2-4) and resides within the subunits of
dinitrogenase (5). FeMo-co consists of iron, sulfur, and
molybdenum atoms in the ratio 7:9:1, and a molecule of homocitrate that
serves as a non-protein ligand to the molybdenum atom (6).
Genetic and biochemical studies in Klebsiella pneumoniae and
Azotobacter vinelandii have revealed that the products of
nifQ, V, B, H,
X, N, and E are involved in the biosynthesis
of FeMo-co (7-11). However, the exact roles played by many of these
nif gene products remain uncertain. A list of the
nif gene products involved in FeMo-co biosynthesis and their
known/postulated roles in this process is given in Table
I. Early on, the studies conducted by
Imperial et al. (12) have made clear that the structural genes encoding dinitrogenase, nifK and D, are not
required for the biosynthesis of the cofactor per se. This
suggested that FeMo-co is synthesized separately and then inserted into
cofactor sites in NifKD.
An in vitro FeMo-co biosynthesis system has been
established, which involves mixing extracts from two A. vinelandii strains with complementary defects in the synthesis of
FeMo-co; alternatively, the addition of the missing component can be
added to complement a particular mutant extract (13). This assay system
requires at least homocitrate, molybdate (as a source of molybdenum),
MgATP, reductant (sodium dithionite), NifNE, NifH, NifB-cofactor
(NifB-co), and NifX.
There is limited information regarding the iron, sulfur, and molybdenum
donors to FeMo-co. The metabolic product of NifB, termed NifB-co, has
been shown to be comprised only of iron and sulfur (14). Studies by
Allen et al. (15) with 55Fe- and
35S-labeled NifB-co have conclusively shown that NifB-co
functions as a specific iron and sulfur donor to FeMo-co. However,
whether NifB-co is the sole iron and sulfur donor to FeMo-co or if
additional components are required for this purpose still needs to be determined.
The in vivo accumulation of molybdenum in A. vinelandii and K. pneumoniae was studied by Pienkos and
Brill (16). They reported the accumulation of molybdenum on a
non-nif protein termed Mo-storage protein (Mo-sto) in
A. vinelandii. The 99Mo incorporation study in a
nifDK mutant of K. pneumoniae, by Ugalde et
al. (17), revealed that the radiolabel accumulated on a 65-kDa
protein. The in vitro FeMo-co biosynthesis system was
utilized by Hoover et al. (4) with various homologs of homocitrate to determine which of the organic acids were able to
support 99Mo incorporation into NifKD. Allen et
al. (18) have used 99Mo and the in vitro
biosynthesis system involving various mutant strains of A. vinelandii and have observed the accumulation of 99Mo
on the non-nif chaperone-protein, gamma.
In the present study, we have used 99Mo and the purified
in vitro FeMo-co biosynthesis system to investigate the
pattern of incorporation of the radiolabel. We report the accumulation
of a 99Mo-containing FeMo-co precursor on NifNE, NifH, and
NifX. We present evidence suggesting that NifH/NifNE complex serves as
the entry point for molybdenum into the FeMo-co biosynthetic pathway
and that NifX may play a role in specifying the organic acid moiety of
FeMo-co.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Leupeptin, phenylmethylsulfonyl fluoride (PMSF),
phosphocreatine, creatine phosphokinase, homocitrate lactone,
D,L-isocitric acid, D-malic acid, 2 ketoglutarate, tricarballylic acid, and ATP (as disodium salt) were
from Sigma Chemical Co. 1,2,4-Butane tricarboxylic acid was from Chem
Service (West Chester, PA). Citric acid was obtained from Aldrich Chem
Co. Tris base, glycerol, and glycine were from Fisher Scientific Co.
Sodium dithionite (DTH) was from Fluka. Acrylamide/bisacrylamide
solutions (37.5%:1%), and SDS-PAGE equipment was from Bio-Rad.
Carrier-free 99Mo was obtained from the Department of
BioMedical Physics, University of Wisconsin-Madison.
Buffers--
25 mM Tris-HCl (pH 7.4) was used
throughout unless otherwise noted. All buffers were sparged with
nitrogen for at least 20 min prior to alternating cycles of evacuation
and flushing with argon on a gassing manifold. DTH was added to a final
concentration of 1 mM. Buffers used for protein
purification contained 0.5 µg/ml leupeptin and 0.2 mM PMSF.
In vitro FeMo-co Synthesis--
The in vitro FeMo-co
synthesis reactions were performed in 9-ml serum vials sealed with
serum stoppers. The vials were repeatedly evacuated and flushed with
argon gas and rinsed with 0.3 ml of anaerobic buffer. The complete
purified in vitro FeMo-co synthesis reaction mixture
contained the following components: 0.1 ml of anaerobic buffer, 0.2 nmol of unlabeled sodium molybdate, 100 nmol of homocitrate that had
been treated with base to cleave the lactone (pH 8.0), 0.2 ml of an
ATP-regenerating system (containing 3.6 mM ATP, 6.3 mM MgCl2, 51 mM creatine phosphate,
20 units/ml creatine phosphokinase, and 6.3 mM DTH in
anaerobic buffer), 10 µl of a solution containing NifB-co (0.4 nmol
of iron/µl), 7.5-30 µg of purified NifNE, 25 µg of purified
NifH, 15 µg of purified NifX, 55 µg of purified apodinitrogenase
( 2 2 2), and
99Mo (1.5 million cpm, prepared in anoxic Tris-HCl buffer
containing 1.7 mM DTH). The total volume of each reaction
mixture was 510 µl. The reactions were incubated at 30 °C for 35 min to allow FeMo-co synthesis and the insertion of the newly formed
FeMo-co into apodinitrogenase. Reactions that were used to monitor only FeMo-co biosynthesis contained all the components listed above except
for apodinitrogenase. The total volume for such reaction mixtures was
490 µl.
Reactions containing various organic acids in place of homocitrate were
performed as described by Imperial et al. (19). The final
concentrations of the various homocitrate analogs in the in
vitro FeMo-co synthesis assay were 8 mM for citrate
and malate, 1.6 mM for isocitrate and 2-ketoglutarate, and
16 mM for tricarballylate and for 1,2,4-butane
tricarboxylate. Solutions of the various homocitrate analogs were
prepared in dilute NaOH and were brought to pH 9.0 prior to their
addition to the assay.
100-µl portions of the reaction mixtures were then subjected to
anoxic native gel electrophoresis. FeMo-co synthesis activity of
duplicate reactions was monitored by the acetylene reduction assay to
demonstrate that all components of the reaction mixture were active and
functional (45).
Definition of Assays--
In vitro FeMo-co synthesis
assays containing all components known to be essential for FeMo-co
synthesis, namely NifNE, NifB-co, NifH, and NifX, as well as
apodinitrogenase, will be referred to as the complete reaction, while
those lacking a specific component will be labeled minus that
particular component. Thus, assays lacking NifB-co will be referred to
as "minus-NifB-co reaction."
Electrophoresis, Immunoblots, and Visualization of
Radioactivity--
Procedures for SDS-PAGE, anoxic native gel
electrophoresis, immunoblotting, and for visualization of radioactivity
have been described previously (20). Proteins were resolved on 7-20%
acrylamide and 0-20% sucrose gradient gels. Proteins in reaction
mixtures including apodinitrogenase were resolved on 5-10% acrylamide
and 0-20% sucrose. After electrophoresis at 100 mV for 18 h, the
gels were dried and exposed to a phosphor screen for 4-6 h. Screens were scanned using a Cyclone storage phosphor system (Packard Instruments). Quantitation of the radiolabel incorporated into proteins
was performed using Optiquant software (Packard Instruments). The
amount of molybdenum incorporated into proteins was estimated from the
known specific activity of 99Mo in the reaction mixture and
the quantitation of the amount of radioactivity in the bands by
comparison with known amounts of 99Mo blotted on a piece of
filter paper.
Purification of Other Components--
Dinitrogenase and NifH
were purified as described previously (21). Gamma protein (NafY) was
purified from an Escherichia coli strain overexpressing the
gamma gene (nafY), as described by Rubio et
al.2 Procedures for the
purification of NifNE, apodinitrogenase, and NifX have been described
by Roll et al. (23), Paustian et al. (24), and
Rangaraj et al. (20), respectively. FeMo-co and NifB-co were
purified as described by Shah et al. (2, 14). Protein was
determined as described previously (25) using bovine serum albumin as standard.
 |
RESULTS |
Incorporation of 99Mo into Components of the In Vitro
FeMo-co Synthesis Reaction Mixture--
Earlier studies have indicated
that the products of nifB, H, N,
E, and X are required for the in vitro
FeMo-co synthesis reaction (10, 13, 14, 26). Apart from the
above-mentioned gene products, NifV and NifQ are also required during
FeMo-co biosynthesis in vivo for the production of
homocitrate and for a proposed molybdenum processing step, respectively
(11, 27, 28). Typically, the in vitro FeMo-co synthesis
reaction involves mixing extracts from different mutants defective in
the synthesis of the cofactor (13). In contrast, the purified in
vitro FeMo-co synthesis system involves the addition of all
components known to be required for cofactor synthesis, in their
purified forms (10). The purified system yields lower FeMo-co synthesis
activity in comparison to a system employing crude cell extracts, thus
suggesting the requirement of other component(s) essential for cofactor
synthesis (10). Apodinitrogenase, NifNE, NifB-co, NifH, and NifX were
purified as described under "Experimental Procedures." The
incorporation of 99Mo into components of the in
vitro FeMo-co synthesis reaction was monitored by separating the
proteins in the reaction mixture on anoxic native gels and by
phosphorimage analyses of these gels (Fig.
1). Assignment of the various bands on
the gel was accomplished by immunoblotting for the relevant proteins on
similar gels. When all components known to be required for FeMo-co
synthesis, namely NifNE, NifH, NifX, NifB-co, MgATP, and homocitrate
are present (lane 1), incorporation of 99Mo into
three distinct bands can be observed. In a minus-homocitrate reaction, as shown in lane 2, there is higher
labeling of NifH as well as incorporation of label into a
slower-migrating band labeled NifNE. An important feature to be noted
here is that the total amount of radiolabel incorporated into the
various proteins is higher in lane 2 versus lane 1 of Fig.
1. This result was observed consistently, and one possible explanation
for this phenomenon is the inability of the proteins in the complete
reaction mixture (lane 1) to bind finished FeMo-co. FeMo-co,
being unstable in aqueous solutions, disintegrates, leading to a lower
accumulation of the total radiolabel in a "complete" reaction
mixture. However, when one of the components necessary for FeMo-co
synthesis is missing from the reaction mixture, the cofactor
biosynthetic pathway is blocked at a particular step. In this scenario,
FeMo-co intermediates are still bound to various proteins, and thus the
total amount of radiolabel in reactions missing an essential component
for cofactor biosynthesis is higher than the reaction containing all the necessary components.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 1.
Phosphorimager analyses of anoxic native gel
illustrating the incorporation of 99Mo into the components
of the purified in vitro FeMo-co synthesis
system. The in vitro FeMo-co synthesis reactions
containing all the components required for the synthesis of FeMo-co
excluding apodinitrogenase were performed as described under
"Experimental Procedures." Lane 1, reaction including
all components required for the biosynthesis of FeMo-co; lane
2, minus-homocitrate reaction; lane 3, minus-MgATP
reaction; lane 4, minus-NifH reaction; lane 5,
minus-NifX reaction; lane 6, minus-NifNE reaction;
lane 7, minus-NifB-co reaction. The table below the figure
indicates the presence (+) or absence ( ) of the particular component.
The positions of NifNE, NifH, and NifX are indicated.
|
|
The minus-MgATP (lane 3), minus-NifH (lane 4),
minus-NifNE (lane 6), and minus-NifB-co (lane 7)
reactions do not show incorporation of radiolabel into any distinct
bands. This suggests that the incorporation of 99Mo into
NifNE, NifH, and NifX is dependent on the presence of MgATP, NifNE,
NifB-co and NifH. The minus-NifX reaction (lane 5), however,
showed the incorporation of 99Mo into NifH and to a lesser
extent into NifNE, indicating that NifX likely plays a role in the
latter part of the cofactor biosynthetic pathway.
Incorporation of 99Mo-containing FeMo-co Precursor into
NifNE--
NifNE is believed to play a catalytic role in the early
part of the FeMo-co biosynthetic pathway (23). Fig. 1 shows that 99Mo incorporation into NifNE is dependent on the presence
of MgATP (lane 3), on NifH (lane 4), and on
NifB-co (lane 7). A homocitrate-deficient reaction
(lane 2) showed a higher level of incorporation of
99Mo into NifNE, suggesting that FeMo-co biosynthesis may
be blocked at the point where homocitrate is added to the FeMo-co
precursor. The addition of homocitrate (lane 1) allowed
cofactor biosynthesis to proceed beyond this point, and consequently a
lower level of labeling of NifNE is observed. The data presented here
suggest that the precursor of FeMo-co on NifNE is
homocitrate-deficient. Because the incorporation of 99Mo is
dependent on the presence of MgATP, NifB-co, and NifH and because NifNE
alone in the presence of MgATP did not show any incorporation of
99Mo (data not shown), we conclude that the radiolabel on
NifNE is not adventitious. Quantitation of the 99Mo label
on NifNE was performed as described under "Experimental Procedures"
and revealed 0.6 nmol of molybdenum per nmol NifNE.
In the above reactions excess NifNE (30 µg) was used to observe the
incorporation of 99Mo label into NifNE. When a catalytic
quantity of NifNE (7.5 µg) was used, 99Mo accumulation on
NifNE was greatly diminished; but this level of NifNE was sufficient
for the radiolabel accumulation on NifH and NifX, as can be observed in
Figs. 2 and
3. Prior to this study, 99Mo-labeling of NifNE has not been observed. Previous
studies (17, 18) have involved the use of crude cell extracts, and two
possible reasons for not observing the incorporation of
99Mo into NifNE could be the interference from other
proteins present in the cell extracts, or that the synthesis of FeMo-co
is allowed to proceed beyond NifNE. The purified in vitro
FeMo-co synthesis reaction is a well-defined system and, being devoid
of other extraneous components present in crude enzyme preparations,
has facilitated the identification of hitherto undetected
incorporation of a FeMo-co precursor into NifNE.

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 2.
Phosphorimager analyses of anoxic native gel
illustrating the incorporation of 99Mo into NifH. The
in vitro FeMo-co synthesis reactions containing all the
components required for the synthesis of FeMo-co excluding
apodinitrogenase were performed as described under "Experimental
Procedures." Lane 1, reaction including all components
required for the biosynthesis of FeMo-co and excluding gamma;
lane 2, minus-homocitrate reaction; lane 3, same
as in lane 1 and including NafY (gamma); lane 4, same as in
lane 1 and including apodinitrogenase
( 2 2 2) (the subunit is
NafY); lane 5, reaction containing only NifH and MgATP. The
table below the figure indicates the presence (+) or absence ( ) of
the particular component. The positions of dinitrogenase, NifH,
NafY-FeMo-co, and NifX are indicated.
|
|

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 3.
Phosphorimager analyses of anoxic native gel
illustrating the organic acid-dependent incorporation of
99Mo into NifX. The in vitro FeMo-co
synthesis reactions containing all the components required for the
synthesis of FeMo-co excluding apodinitrogenase were performed as
described under "Experimental Procedures." Lane 1,
reaction including homocitrate; lane 2, reaction excluding
organic acid; lane 3, reaction including isocitrate;
lane 4, reaction including malate; lane 5,
reaction including 1,2,4-butane tricarboxylate; lane 6,
reaction including tricarballylate; lane 7, reaction
including citrate; lane 8, reaction including
2-ketoglutarate. The positions of NifH and NifX are indicated.
|
|
Incorporation of 99Mo-containing FeMo-co Precursor into
NifH--
The purified in vitro FeMo-co synthesis system
containing NifH, NifX, NafY, apodinitrogenase, and catalytic amounts of
NifNE (7.5 µg) was utilized for the investigation of 99Mo
incorporation into NifH. The results shown in Fig. 1 indicate that
significant incorporation of the heterometal into NifH occurred only
when components known to be required for FeMo-co biosynthesis were
present in the reaction mixture. For example, when MgATP, NifNE, or
NifB-co (Fig. 1, lanes 3, 6, and 7) were not
included in the reaction mixture, no incorporation of 99Mo
into NifH could be observed. However, a minimal level of radiolabel was
incorporated into NifH when a high concentration of NifH (>5 nmol) was
incubated with 99Mo and MgATP (Fig. 2, lane 5).
This low level of nonspecific binding to molybdenum possibly occurs at
the PO43 -binding site in NifH. It should be
noted here that Georgiadis et al. (29) have reported the
presence of a molybdenum atom in the structure of NifH. In a
minus-homocitrate reaction mixture, a higher level of incorporation was
consistently observed (lane 2 in Figs. 1 and 2), suggesting
that the FeMo-co precursor on NifH lacked homocitrate. Quantitation of
radiolabel on NifH performed as described under "Experimental
Procedures" indicated 0.54 nmol of molybdenum per nmol NifH. Upon the
addition of the non-nif chaperone protein NafY (gamma) to
the reaction mixture (Fig. 2, lane 3), the label is seen on
a slightly faster migrating species than NifH that is labeled NafY, as
judged by the migrating pattern of NafY-FeMo-co species on similar gels
as determined by immunoblotting. This demonstrates a transfer of
finished FeMo-co from NifH and NifX to NafY. Homer et al.
(30) have shown that NafY specifically binds FeMo-co, by in
vitro as well as in vivo studies. When purified apodinitrogenase ( 2 2 2) is
added to the reaction mixture (lane 4), the 99Mo
label can be observed at the dinitrogenase position with a concomitant
decrease in the amount of label associated with NifH and with NifX,
indicating that the completed FeMo-co has been inserted into apodinitrogenase.
Incorporation of 99Mo-containing FeMo-co Precursor into
NifX--
Using the purified in vitro FeMo-co synthesis
system by Shah et al. (10), NifX has been shown to be
required for FeMo-co synthesis. When all components known to be
required for FeMo-co synthesis are present in the reaction mixture
including NifH, NifX, and catalytic amounts of NifNE (7.5 µg),
99Mo-radiolabel is observed on NifX, apart from NifNE and
NifH (Fig. 1). This incorporation of 99Mo into NifX is
dependent on the presence of MgATP, NifH, NifNE, and NifB-co (Fig. 1,
lanes 3, 4 and 6, 7). There was no incorporation of the radiolabel when NifX was incubated by itself with
99Mo in the presence or absence of MgATP (data not shown).
However, a minus-NifX reaction could support the incorporation into
NifNE as well as NifH (Fig. 1, lane 5), suggesting that NifX
plays a role in the latter part of the FeMo-co biosynthetic pathway.
The effect of various organic acids on the incorporation of
99Mo into the components of the purified in
vitro FeMo-co biosynthesis system was studied by including various
organic acids in the reaction mixture. The reaction mixtures included
NifH, NifX, and catalytic amounts of NifNE (7.5 µg) and were
performed as described in the "Experimental Procedures" section.
The results of this study, shown in Fig. 3, indicate that there is
incorporation of 99Mo into NifH as well as NifX. However,
while the incorporation of the radiolabel into NifH occurred no matter
what organic acid was present in the reaction mixture, the
incorporation into NifX was dependent on the presence of certain
organic acids. Only homocitrate, isocitrate, malate, citrate, and
2-ketoglutarate could support the incorporation of 99Mo
into NifX (Fig. 3, lanes 1, 3, 4, and 7, 8). The
organic acids 1,2,4-butane tricarboxylate and tricarballylate
(lanes 5 and 6) did not support the synthesis of FeMo-co and
the incorporation of radiolabel into NifX. Previous studies by Hoover
et al. (4) and by Imperial et al. (19) have shown
that both organic acids 1,2,4-butane tricarboxylate and tricarballylate
did not support the incorporation of 99Mo into
dinitrogenase when homocitrate was replaced with these organic acids.
Both 1,2,4-butane tricarboxylate and tricarballylate have also been
shown to be incapable of supporting substrate reduction activity. In
the present study we have shown that there is minimal incorporation of
the radiolabel into NifX when the above organic acids are used in the
in vitro FeMo-co biosynthesis system lacking apodinitrogenase. These data suggest a role for NifX in specifying the
organic acid moiety of FeMo-co. Interestingly, substitution of citrate
for homocitrate seems to enhance accumulation of a FeMo-co precursor
(or FeMo-co) on NifX (lane 7). This is consistent with
previous results by Hoover et al. (4).
Based on the above results, it seemed likely that NifX played a role in
the latter part of the cofactor biosynthetic pathway. To further
analyze the role of NifX, we monitored the incorporation of
99Mo label into apodinitrogenase in reactions including and
excluding NifX. The in vitro FeMo-co biosynthesis assays
were performed as described under "Experimental Procedures." The
complete reaction (Fig. 4, lane
1) shows the incorporation of 99Mo into dinitrogenase.
A specific activity of 134.5 nmol per min per mg of protein was
obtained and this suggested the formation of FeMo-co and its insertion
into apodinitrogenase
( 2 2 2). In the absence of
NifB-co, NifH, or MgATP there was no incorporation of the radiolabel
into dinitrogenase. However, a minus-NifX reaction (lane 4)
showed a much lower level of label incorporated into dinitrogenase.
This reaction also showed a lower specific activity (29.8 nmol) than
the reaction containing NifX. Quantitation of the radiolabel on
dinitrogenase revealed ~4.5 times lower level of label on the
dinitrogenase band in the minus-NifX reaction when compared with the
reaction that contained NifX. These data suggest a role for NifX in the
insertion process of the cofactor into apodinitrogenase; however, this
role might not be absolutely required.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 4.
Phosphorimager analyses of anoxic native gel
illustrating the NifX-dependent incorporation of
99Mo into apodinitrogenase. The in vitro
FeMo-co synthesis reactions containing all the components required for
the synthesis of FeMo-co including apodinitrogenase were performed as
described under "Experimental Procedures." Lane 1,
reaction including all components required for the biosynthesis of
FeMo-co and apodinitrogenase
( 2 2 2); lane 2,
minus-NifB-co reaction; lane 3, minus-NifH reaction;
lane 4, minus-NifX reaction; lane 5, minus-MgATP
reaction. The table below the figure indicates the presence (+) or
absence ( ) of the particular component. The position of dinitrogenase
is indicated. Specific activities (nmol C2H4
per min per mg apodinitrogenase) are reported; n.d., not
determined.
|
|
 |
DISCUSSION |
We have studied the accumulation of 99Mo into proteins
involved in the biosynthesis of FeMo-co. The salient features of the present study are: 1) NifNE, NifH, and NifX accumulate
99Mo-FeMo-co precursors; 2) transfer of 99Mo
label from NifH and NifX to NafY or apodinitrogenase, indicating the
presence of completed FeMo-co; 3) involvement of NifX in specifying organic acid moiety of FeMo-co; and 4) requirement of NifNE and NifH
for the incorporation of molybdenum into the FeMo-co biosynthetic pathway.
Based on the results presented in this study and from previous studies
with 55Fe-NifB-co (20), the following hypothesis for the
biosynthesis of FeMo-co is consistent with our results. NifNE binds
NifB-co; then NifH binds the NifNE-NifB-co complex. Our previous
results suggest that NifH and NifNE form a complex (42), and results presented here suggest that only when both NifH and NifNE are present
is either protein capable of binding molybdenum. Hence, we propose that
the addition of molybdenum to NifB-co occurs within the
NifNE-NifB-co-NifH complex to yield a Mo-containing FeMo-co precursor.
The binding of NifB-co to NifNE is one of the early steps in FeMo-co
biosynthesis. This event has been observed as a change in the mobility
of NifNE on anoxic native gels by Roll et al. (23) and by
visualizing 55Fe label on NifNE when radiolabeled NifB-co
was used by Allen et al. (15) and Rangaraj et al.
(20). Because the binding of NifB-co to NifNE does not require the
presence of any additional factors such as MgATP or NifH, this step has
been suggested as one of the first steps in the cofactor biosynthetic
pathway. It is not yet known if any change is brought about in NifB-co
upon its binding to NifNE. The role of NifNE in FeMo-co biosynthesis is
thought to be that of a scaffold protein upon which FeMo-co is
synthesized (44). This is supported by the facts that NifNE and
dinitrogenase share high sequence similarity and that apodinitrogenase is not required for FeMo-co synthesis. In A. vinelandii,
NifNE is absolutely required for the biosynthesis of FeMo-co as
nifN or E mutants show a definite
nif phenotype. However, a recent report by
Siemann et al. (31) reveals that in Rhodobacter
capsulatus NifNE is not essential for the biosynthesis
of FeMo-co, though its presence greatly enhances the content of intact
FeMo-co-containing NifDK.
NifB-co has been shown to function as a specific iron and sulfur donor
to FeMo-co. It is not known whether all of the iron and sulfur of
FeMo-co are donated solely by NifB-co, but it seems likely that a major
portion of the iron and sulfur in FeMo-co is derived from NifB-co.
Though the structure of NifB-co is yet to be solved, it is known that
NifB-co contains iron and sulfur, but not molybdenum (14). NifU and
NifS are believed to be involved in mobilizing iron and sulfur (32,
33), respectively, into NifB for the synthesis of NifB-co because
NifB-co levels in K. pneumoniae mutants lacking
nifS and nifU are greatly
decreased.3
The next step in FeMo-co biosynthesis involves NifH. NifH has been
shown to be a multifunctional "moonlighting" protein (34) playing
diverse roles in the nitrogenase enzyme system: 1) substrate reduction
wherein it functions as the obligate electron donor to dinitrogenase
(35); 2) the maturation of apodinitrogenase wherein its presence is
required for associating NafY with the NafY-deficient apodinitrogenase
(36); and 3) the biosynthesis of FeMo-co (8, 26, 37). Its role in
substrate reduction is best understood, while the specific role(s) of
NifH in the latter two processes is obscure. The facts that several
site-specifically altered forms of NifH showing altered MgATP
reactivities function in cofactor biosynthesis (38-40) and that the
4Fe-4S cluster of the protein is not required for its function in this
process (41) argue for a role that is very different from the NifH role
in substrate reduction. We have shown in the present study that a 99Mo-labeled FeMo-co precursor accumulates on NifH and that
this accumulation of radiolabel is dependent upon the presence of
NifB-co and NifNE as well as MgATP. Because the presence of both NifNE and NifH is required to observe any accumulation of 99Mo,
we propose that molybdenum is added to the FeMo-co precursor bound by
the NifNE-NifH complex. This hypothesis is further strengthened by the
study of L127 NifH (a site-specifically altered form of NifH) and
NifNE that suggested an interaction of NifH with only the NifB-co
associated form of NifNE (42). Studies with 55Fe-NifB-co
also show accumulation of a FeMo-co precursor on NifH (20). In a
minus-NifH reaction there is no accumulation of molybdenum on any
protein, suggesting that NifH is necessary for the entry of molybdenum
into the FeMo-co biosynthetic pathway. Data presented in this study
suggest that the action of NifH occurs prior to the addition of
homocitrate, as a minus-homocitrate reaction showed a higher level of
NifH labeling than a reaction wherein homocitrate was present. We have
presented evidence for the involvement of NifH along with NifNE in the
addition of heterometal, molybdenum, to the cofactor precursor. In this
context, it seems likely that VnfH and AnfH, NifH counterparts in the
vnf and the anf systems, serve in a similar
manner and specify V and Fe respectively, during FeV-co and FeFe-co biosyntheses.
The next step in FeMo-co biosynthesis involves the action of NifX. The
presence of NifX is not necessary for the accumulation of
99Mo label on NifH. This suggests that NifX plays a role in
the latter part of the FeMo-co biosynthetic pathway. In a previous study we have shown that NifX is capable of binding NifB-co and that a
55Fe-labeled FeMo-co precursor accumulated on NifX (20).
Recent data suggest that NifX-bound NifB-co can be transferred to
NifNE.2 However, whether this transfer is physiologically
relevant remains to be determined. In the present study, we have shown
the homocitrate-dependent labeling of NifX, suggesting a
role for NifX in specifying the organic acid moiety in FeMo-co. Also,
an enhancement in incorporation of the 99Mo-radiolabel into
apodinitrogenase in the presence of NifX that also correlates with
C2H2 reduction activity has been observed. This
suggests a role for NifX in the cofactor insertion process. In this
context, VnfX, the NifX homolog in the vanadium nitrogenase system, has
also been shown to accumulate a FeV-co precursor, and Rüttimann
et al. (43) have shown the homocitrate-dependent transfer of the VnfX-bound FeV-co precursor to apodinitrogenase.
The non-nif protein NafY (aka gamma) has been postulated to
function as a chaperone-insertase in the biosynthesis of NifDK. Evidence for the transfer of 99Mo label from NifH and NifX
to NafY is seen in Fig. 2, suggesting the completion of FeMo-co
synthesis. Homer et al. (30) have shown that NafY binds
FeMo-co specifically and have postulated a role for NafY in the
cofactor insertion process. However, Rubio et al. (22) have
shown that nafY mutants exhibit a nif phenotype only under stress conditions. One interpretation of their data is that
NafY is required for the stability of apodinitrogenase in an open
conformation that is favorable to the insertion of FeMo-co.
In vivo, FeMo-co biosynthesis might not occur in sequential
steps on uncomplexed proteins. A FeMo-co biosynthetic complex comprised
of NifNE, NifX, and NifH might possibly exist, to which NifB-co, Mo,
and homocitrate are supplied by NifB, NifQ, and NifV, respectively. The
FeMo-co produced in the complex might be bound by NafY, which delivers
the cofactor to apodinitrogenase. Results presented in this study and
other studies were obtained with the use of either purified proteins or
the use of cell-free extracts. We believe that the FeMo-co biosynthetic
complex in these cases has been teased apart so that FeMo-co
biosynthesis can be studied as several individual steps rather than
as one concerted, continuous event.
Though the sequence of steps in the FeMo-co biosynthetic pathway is
better understood at present than a few years ago, the exact roles
played by NifH and NifX in this process remain to be explored.
Questions concerning the role of MgATP and whether nucleotide
hydrolysis is required for FeMo-co synthesis also remain to be
addressed. At some stage reductant is required during the biosynthesis
of FeMo-co, presumably for the reduction of Mo(VI) to Mo(IV), the
formal oxidation state proposed for molybdenum in FeMo-co (46). The
exact step at which reductant is required needs to be addressed. Future
studies will be aimed at answering the above questions.
 |
ACKNOWLEDGEMENTS |
We thank Luis Rubio for purified gamma
protein. We thank Vinod Shah, Gary Roberts, and Carmen
Rüttimann-Johnson for helpful discussions. We thank Laura
Vanderploeg for help with figures.
 |
FOOTNOTES |
*
This work has been supported by National Institutes of
Health/NIGMS Grant GM35332 (to P. W. L.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Pierce Chemical Co., 3747 N. Meridian Road,
Rockford, IL 61105.
To whom correspondence should be addressed: College of Natural
Resources, University of California, Berkeley, 101 Giannini Hall, Rm.
3100, Berkeley, CA 94720. Tel.: 510-642-7171; Fax: 510-642-4612; E-mail: pludden@nature.berkeley.edu.
Published, JBC Papers in Press, August 9, 2002, DOI 10.1074/jbc.M204581200
3
P. Rangaraj and P. W. Ludden, unpublished data.
2
Rubio et al., unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
FeMo-co, iron-molybdenum cofactor;
DTH, sodium dithionite.
 |
REFERENCES |
| 1.
|
Burris, R. H.
(1991)
J. Biol. Chem.
266,
9339-9342[Free Full Text]
|
| 2.
|
Shah, V. K.,
and Brill, W. J.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
3249-3253[Abstract/Free Full Text]
|
| 3.
|
Hawkes, T. R.,
McLean, P. A.,
and Smith, B. E.
(1984)
Biochem. J.
217,
317-321[Medline]
[Order article via Infotrieve]
|
| 4.
|
Hoover, T. R.,
Imperial, J.,
Liang, J.,
Ludden, P. W.,
and Shah, V. K.
(1988)
Biochemistry
27,
3647-3652[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kim, J.,
and Rees, D. C.
(1992)
Nature
360,
553-560[CrossRef]
|
| 6.
|
Kim, J.,
and Rees, D. C.
(1992)
Science
257,
1677-1682[Abstract/Free Full Text]
|
| 7.
|
Roberts, G. P.,
and Brill, W. J.
(1980)
J. Bacteriol.
144,
210-221[Abstract/Free Full Text]
|
| 8.
|
Filler, W. A.,
Kemp, R. M., Ng, J. C.,
Hawkes, T. R.,
Dixon, R. A.,
and Smith, B. E.
(1986)
Eur. J. Biochem.
160,
371-377[Medline]
[Order article via Infotrieve]
|
| 9.
|
McLean, P. A.,
Smith, B. E.,
and Dixon, R. A.
(1983)
Biochem. J.
211,
589-597[Medline]
[Order article via Infotrieve]
|
| 10.
|
Shah, V. K.,
Rangaraj, P.,
Chatterjee, R.,
Allen, R. M.,
Roll, J. T.,
Roberts, G. P.,
and Ludden, P. W.
(1999)
J. Bacteriol.
181,
2797-2801[Abstract/Free Full Text]
|
| 11.
|
Imperial, J.,
Ugalde, R. A.,
Shah, V. K.,
and Brill, W. J.
(1984)
J. Bacteriol.
158,
187-194[Abstract/Free Full Text]
|
| 12.
|
Imperial, J.,
Shah, V. K.,
Ugalde, R. A.,
Ludden, P. W.,
and Brill, W. J.
(1987)
J. Bacteriol.
169,
1784-1786[Abstract/Free Full Text]
|
| 13.
|
Shah, V. K.,
Imperial, J.,
Ugalde, R. A.,
Ludden, P. W.,
and Brill, W. J.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
1636-1640[Abstract/Free Full Text]
|
| 14.
|
Shah, V. K.,
Allen, J. R.,
Spangler, N. J.,
and Ludden, P. W.
(1994)
J. Biol. Chem.
269,
1154-1158[Abstract/Free Full Text]
|
| 15.
|
Allen, R. M.,
Chatterjee, R.,
Ludden, P. W.,
and Shah, V. K.
(1995)
J. Biol. Chem.
270,
26890-26896[Abstract/Free Full Text]
|
| 16.
|
Pienkos, P. T.,
and Brill, W. J.
(1981)
J. Bacteriol.
145,
743-751[Abstract/Free Full Text]
|
| 17.
|
Ugalde, R. A.,
Imperial, J.,
Shah, V. K.,
and Brill, W. J.
(1984)
J. Bacteriol.
159,
888-893[Abstract/Free Full Text]
|
| 18.
|
Allen, R. M.,
Roll, J. T.,
Rangaraj, P.,
Shah, V. K.,
Roberts, G. P.,
and Ludden, P. W.
(1999)
J. Biol. Chem.
274,
15869-15874[Abstract/Free Full Text]
|
| 19.
|
Imperial, J.,
Hoover, T. R.,
Madden, M. S.,
Ludden, P. W.,
and Shah, V. K.
(1989)
Biochemistry
28,
7796-7799[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Rangaraj, P.,
Ruttimann-Johnson, C.,
Shah, V. K.,
and Ludden, P. W.
(2001)
J. Biol. Chem.
276,
15968-15974[Abstract/Free Full Text]
|
| 21.
|
Shah, V. K.,
and Brill, W. J.
(1973)
Biochim. Biophys. Acta
305,
445-454[Medline]
[Order article via Infotrieve]
|
| 22.
|
Rubio, L. M.,
Rangaraj, P.,
Homer, M. J.,
Roberts, G. P.,
and Ludden, P. W.
(2002)
J. Biol. Chem.
277,
14299-14305[Abstract/Free Full Text]
|
| 23.
|
Roll, J. T.,
Shah, V. K.,
Dean, D. R.,
and Roberts, G. P.
(1995)
J. Biol. Chem.
270,
4432-4437[Abstract/Free Full Text]
|
| 24.
|
Paustian, T. D.,
Shah, V. K.,
and Roberts, G. P.
(1990)
Biochemistry
29,
3515-3522[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Smith, P. K.,
Krohn, R. I.,
Hermanson, A. K.,
Mallia, A. K.,
Gartner, F. H.,
Provezano, M. D.,
Fujimoto, E. K.,
Goeke, N. M.,
Olson, B. J.,
and Klenk, D. C.
(1985)
Anal. Biochem.
150,
175-179
|
| 26.
|
Shah, V. K.,
Hoover, T. R.,
Imperial, J.,
Paustian, T. D.,
Roberts, G. P.,
and Ludden, P. W.
(1988)
in
Nitrogen Fixation: Hundred Years After
(Bothe, H.
, de Bruijn, F. J.
, and Newton, W. E., eds)
, pp. 115-120, Gustav Fischer, Cologne
|
| 27.
|
Hoover, T. R.,
Shah, V. K.,
Roberts, G. P.,
and Ludden, P. W.
(1986)
J. Bacteriol.
167,
999-1003[Abstract/Free Full Text]
|
| 28.
|
Hoover, T. R.,
Robertson, A. D.,
Cerny, R. L.,
Hayes, R. N.,
Imperial, J.,
Shah, V. K.,
and Ludden, P. W.
(1987)
Nature
329,
855-857[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Georgiadis, M. M.,
Komiya, H.,
Chakrabarti, P.,
Woo, D.,
Kornuc, J. J.,
and Rees, D. C.
(1992)
Science
257,
1653-1659[Abstract/Free Full Text]
|
| 30.
|
Homer, M. J.,
Dean, D. R.,
and Roberts, G. P.
(1995)
J. Biol. Chem.
270,
24745-24752[Abstract/Free Full Text]
|
| 31.
|
Siemann, S.,
Schneider, K.,
Behrens, K.,
Knochel, A.,
Klipp, W.,
and Muller, A.
(2001)
Eur. J. Biochem.
268,
1940-1952[Medline]
[Order article via Infotrieve]
|
| 32.
|
Fu, W.,
Jack, R. F.,
Morgan, T. V.,
Dean, D. R.,
and Johnson, M. K.
(1994)
Biochemistry
33,
13455-13463[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Zheng, L.,
White, R. H.,
Cash, V. L.,
Jack, R. F.,
and Dean, D. R.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
2754-2758[Abstract/Free Full Text]
|
| 34.
|
Jeffery, C. J.
(1999)
Trends Biochem. Sci.
24,
8-11[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Ljones, T.,
and Burris, R. H.
(1972)
Biochim. Biophys. Acta
275,
93-101[Medline]
[Order article via Infotrieve]
|
| 36.
|
Allen, R. M.,
Homer, M. J.,
Chatterjee, R.,
Ludden, P. W.,
Roberts, G. P.,
and Shah, V. K.
(1993)
J. Biol. Chem.
268,
23670-23674[Abstract/Free Full Text]
|
| 37.
|
Robinson, A. C.,
Dean, D. R.,
and Burgess, B. K.
(1987)
J. Biol. Chem.
262,
14327-14332[Abstract/Free Full Text]
|
| 38.
|
Gavini, N.,
and Burgess, B. K.
(1992)
J. Biol. Chem.
267,
21179-21186[Abstract/Free Full Text]
|
| 39.
|
Wolle, D.,
Dean, D. R.,
and Howard, J. B.
(1992)
Science
258,
992-995[Abstract/Free Full Text]
|
| 40.
|
Rangaraj, P.,
Ryle, M. J.,
Lanzilotta, W. N.,
Ludden, P. W.,
and Shah, V. K.
(1999)
J. Biol. Chem.
274,
19778-19784[Abstract/Free Full Text]
|
| 41.
|
Rangaraj, P.,
Shah, V. K.,
and Ludden, P. W.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
11250-11255[Abstract/Free Full Text]
|
| 42.
|
Rangaraj, P.,
Ryle, M. J.,
Lanzilotta, W. N.,
Goodwin, P. J.,
Dean, D. R.,
Shah, V. K.,
and Ludden, P. W.
(1999)
J. Biol. Chem.
274,
29413-29419[Abstract/Free Full Text]
|
| 43.
|
Rüttimann-Johnson, C.,
Rangaraj, P.,
Shah, V. K.,
and Ludden, P. W.
(2001)
J. Biol. Chem.
276,
4522-4526[Abstract/Free Full Text]
|
| 44.
|
Brigle, K. E.,
Weiss, H. C.,
Newton, W. E.,
and Dean, D. R.
(1987)
J. Bacteriol.
169,
1547-1553[Abstract/Free Full Text]
|
| 45.
|
Shah, V. K.,
Ugalde, R. A.,
Imperial, J.,
and Brill, W. J.
(1985)
J. Biol. Chem.
260,
3891-3894[Abstract/Free Full Text]
|
| 46.
|
Coucouvanis, D.
(1993)
in
Molybdenum Enzymes, Cofactors and Model Systems
(Steifel, E. I.
, Coucouvanis, D.
, and Newton, W. E., eds)
, pp. 304-331, ACS Press, Washington, D. C.
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. A. Hernandez, L. Curatti, C. P. Aznar, Z. Perova, R. D. Britt, and L. M. Rubio
From the Cover: Metal trafficking for nitrogen fixation: NifQ donates molybdenum to NifEN/NifH for the biosynthesis of the nitrogenase FeMo-cofactor
PNAS,
August 19, 2008;
105(33):
11679 - 11684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Soboh, R. Y. Igarashi, J. A. Hernandez, and L. M. Rubio
Purification of a NifEN Protein Complex That Contains Bound Molybdenum and a FeMo-Co Precursor from an Azotobacter vinelandii {Delta}nifHDK Strain
J. Biol. Chem.,
December 1, 2006;
281(48):
36701 - 36709.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hu, M. C. Corbett, A. W. Fay, J. A. Webber, K. O. Hodgson, B. Hedman, and M. W. Ribbe
From the Cover: Nitrogen Fixation Special Feature: Nitrogenase Fe protein: A molybdate/homocitrate insertase
PNAS,
November 14, 2006;
103(46):
17125 - 17130.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Curatti, P. W. Ludden, and L. M. Rubio
From the Cover: NifB-dependent in vitro synthesis of the iron-molybdenum cofactor of nitrogenase
PNAS,
April 4, 2006;
103(14):
5297 - 5301.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.-S. Steunou, D. Bhaya, M. M. Bateson, M. C. Melendrez, D. M. Ward, E. Brecht, J. W. Peters, M. Kühl, and A. R. Grossman
From the Cover: In situ analysis of nitrogen fixation and metabolic switching in unicellular thermophilic cyanobacteria inhabiting hot spring microbial mats
PNAS,
February 14, 2006;
103(7):
2398 - 2403.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Hu, A. W. Fay, and M. W. Ribbe
Identification of a nitrogenase FeMo cofactor precursor on NifEN complex
PNAS,
March 1, 2005;
102(9):
3236 - 3241.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|